
--- Page 1 ---
UUID:7FEC6780-415F-42E4-B996-E091CA424621 TCGA-M -A6BN-01A-PR Redacted THIS IS A CONFIDENTIAL AND PRIVILEGED COMMUNICATION PLEASE DISPOSE OF PAPER COPIES APPROPRIATELY Printed by: Name: Age: Test Name: F/S PLEURAL TUMOR{MASS Test Date: Ordered By: COLLECTION DATE: IeD-o.3 SPECIMEN NUMBER: SPECIMENS: 905213 1. F/S PLEURAL TUMOR 2. MASS  5/16/13 DIAGNOSIS: 1. PLEUrA, RIght: BIOPSy  - MALIGNANT EPITHELIOID MESOTHELIOMA. 2. PLEURA: BIOPSY - malignant epithelioid mEsotheliomA. COMMENT: Immunohistochemical study demonstrates the tumor is. positive diffusely for cytokeratin (AE1/AE3) and CK5/6, and focally. positive for calretinin and wT1. The tumor is negative for mCEA,. Ber-EP4 (rare cells +), and TTF1. The findings support the diagnosis. This case has been reviewed intradepartmentally. Pathologist CLINICAL HISTORY AND PRE-OPERATIVE DIAGNOSIS: Lung mass, right MACROSCOPIC DESCRIPTION: The specimen is received in two parts labeled with the patient's name. 1. Part one is received fresh labeled 'pleural tumor'. It consists of three fragments of tan soft tissue that range in size from 0.2 x 0.2 x 0.2 to 1 x 0.4 x 0.2 cm. Entirely submitted for frozen section. 2. Part tow is received fresh labeled with 'pleural tumor'. It consists of one 1.4 x 1.2 x 0.3 cm piece of tan soft tissue. One 0.8 cm tan firm plaque is noted on the surface. The specimen is serially sectioned and entirely submitted. SUMMARY OF SECTIONS 1A in toto 2A in toto

--- Page 2 ---
SPECIAL PROCEDURES: AE1/AE3, Calretinin, WT1, Ber-EP4, mCEA, CK5/6, TTF1 INTRA - OPERATIVE CONSULTATION: 1. Pleural tumor; frozen section Malignant epithelioid tumor, favor mesothelioma. Results. reported by back by Intra-Operative Consultation #1 performed by. Electronically signed Final Diaanosis performed by Electronically signed The electronic signature attests that the named Attending. Pathologist has evaluated the specimen referred to in the signed section of the report and formulated the diagnosis therein. This report may include one or more immunohistochemical stain results that use analyte specific reagents. The tests were developed and their performance characteristics determined by They have not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.